Angus Grant, PhD, is a pharmaceutical and biotechnology executive with experience in regulatory affairs, business development, and corporate alliances.
Dr. Grant currently serves as Chief Executive Officer for the Dementia Discovery Fund (DDF). Prior to joining the DDF, he served in various executive roles at Celgene including Vice President of North American Regulatory Affairs (RA), Head of Europe RA, Vice President of Business Development and Global Alliances and Corporate Vice President of Business Development. Throughout his tenure, Dr. Grant managed over 60 collaborations and investments with pharmaceutical and biotech partners. He previously worked at Novartis, Merck KGaA, Rhone Poulanc-Rohrer, SmithKline Beecham, and the U.S. Food and Drug Administration. In addition to Caraway Therapeutics, Dr. Grant serves on the boards of MaRS Innovation, Tiaki Therapeutics, and Cerevance.
He received a bachelor’s degree from the University of Richmond, his PhD in anatomy & immunology from the Medical College of Virginia, and completed his post-doctoral training at the National Cancer Institute in Bethesda.